🇺🇸 FDA
Patent

US 8916570

A3 adenosine receptor agonists and antagonists

granted A61PA61P1/00A61P11/00

Quick answer

US patent 8916570 (A3 adenosine receptor agonists and antagonists) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 23 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61P, A61P1/00, A61P11/00, A61P11/06, A61P13/12